Drugs

Plausible Mechanism Faces Challenges: Commentary

While FDA’s recently introduced Plausible Mechanism Framework is designed to accelerate development of individualized therapies for rare disease patients, significant operational hurdles remain before the approach can be broadly implemented, according to a commentary published 6/15 by Steven Ringel, founder and chief executive of Nome Therapeutics.

The framework is intended to establish a regulatory pathway for highly individualized therapies where conventional clinical trial requirements may not be feasible. Under the framework, sponsors may be able to demonstrate efficacy through biological proof of concept, including evidence that a therapy addresses a disease-causing genetic defect and produces the intended molecular effect.

Ringel described the framework as a major milestone for the rare disease community, noting that approximately 10,000 rare diseases affect an estimated 30 million Americans and that roughly 95% lack approved treatments. "The framework gives permission to act," Ringel wrote, arguing that the next challenge is building the infrastructure necessary to translate regulatory flexibility into treatments that reach patients.

According to Ringel, five major non-regulatory barriers must be addressed. For example, manufacturing capacity remains a significant constraint. Current contract manufacturing systems are designed for large production runs rather than therapies intended for a single patient. Ringel pointed to federal efforts by the Advanced Research Projects Agency for Health, including the THRIVE and GIVE programs, which aim to create scalable manufacturing platforms for precision genetic medicines.

Ringel also noted artificial intelligence could play a key role in overcoming some challenges. Potential applications include matching patients with development partners, streamlining regulatory documentation, coordinating manufacturing schedules and capturing outcomes data in formats suitable for health economic analyses.

"The science is ready," Ringel wrote. "The only question left is whether the field can build the operational infrastructure to deliver these treatments to every family who needs them."

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome